EUVIMEDEUVIMED entdecken
Open Access

Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations

Jordan J Feld iD, Julie Bruneau, Gregory J Dore, Marc G Ghany, Bettina Hansen, Mark Sulkowski, David L Thomas

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Jordan J Feld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Hepatitis C, Vaccines, Hepatitis C, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, US National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. The primary endpoint would be HCV clearance by 24 weeks post-inoculation, recognizing that the prevention of chronic infection would be the primary goal of HCV vaccine candidates. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis CVaccinesHepatitis C, ChronicHumansHepacivirusSample SizeAntiviral Agents

Stichwörter der Autor:innen

challenge modelcontrolled human infection modelhepatitis C virustrial designvaccine

Substanzen

VaccinesAntiviral Agents

Autor:innen und Institutionen

  • Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montreal, Canada.
  • Kirby Institute, University of New South Wales, Sydney, Australia.
  • Liver Diseases Branch, National Institutes of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland, USA.
  • Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
  • Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Jordan J Feld

Förderung

  • NIDA NIH HHS
  • US National Institutes of Health

Zitieren

APA

Feld, J. J., Bruneau, J., Dore, G. J., Ghany, M. G., Hansen, B., Sulkowski, M., & Thomas, D. L. (2023). Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad362

Vancouver

Feld JJ, Bruneau J, Dore GJ, Ghany MG, Hansen B, Sulkowski M, et al. Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad362

BibTeX
@article{Feld2023,
  author = {Feld, Jordan J and Bruneau, Julie and Dore, Gregory J and Ghany, Marc G and Hansen, Bettina and Sulkowski, Mark and Thomas, David L},
  title = {Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad362}
}
Kostenlos starten →